Expertise in
8
conditions

Takaaki Tokito

Kurume, JP 
Expertise in
8
conditions
Kurume, JP 

Overview

Takaaki Tokito practices practicing medicine in Kurume, Japan.

Tokito is highly rated in 8 conditions, according to our data. Their clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, EGFR Positive Lung Cancer, Febrile Neutropenia, and Tissue Biopsy.

They are actively involved in clinical research, co-authoring 93 peer reviewed articles and participating in 2 clinical trials.

Locations

Kurume, Japan
Other Locations
Sagamihara, Japan
Kanagawa, Japan
Fukuoka, 8300011, Japan
Shimonagakubo, 4118777, Japan
Shizuoka, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)
A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)
Enrollment Status: Completed
Publish Date: August 21, 2026
Intervention Type: Drug
Study Drugs: Tepotinib, Osimertinib
Study Phase: Phase 2
A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)
A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)
Enrollment Status: Active_not_recruiting
Publish Date: July 14, 2026
Intervention Type: Drug
Study Drug: Tepotinib
Study Phase: Phase 2
View 1 Less Clinical Trial

93 Total Publications

Authors' reply to letter by Martinod et al. on rationale for using lenvatinib as an urgent initial therapy in thyroid cancer with remarkable laryngotracheal invasion.
Authors' reply to letter by Martinod et al. on rationale for using lenvatinib as an urgent initial therapy in thyroid cancer with remarkable laryngotracheal invasion.
Journal: European thyroid journal
Published: November 26, 2025

Frequently Asked Questions about Takaaki Tokito

Is Takaaki Tokito a top-rated expert for Non-Small Cell Lung Cancer (NSCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Takaaki Tokito is classified as an Distinguished expert for Non-Small Cell Lung Cancer (NSCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Takaaki Tokito participate in research or clinical trials?

Yes. Takaaki Tokito has published 93 articles and abstracts on conditions like Non-Small Cell Lung Cancer (NSCLC). You can view a list of Takaaki Tokito's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Tokito's expertise for a condition
ConditionClose
    View All 24 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile